Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
•
Endocrinology
•
Primary Care
Would you prescribe semaglutide for weight gain from androgen deprivation therapy for prostate cancer?
Related Questions
What data support the use of continuing GnRH therapy "backbone" in metastatic castration resistant prostate cancer (mCRPC) receiving additional therapies?
For patients with oligo-progressive prostate cancer fit for metastasis-directed therapy but ineligible for radiotherapy or surgery, how do you decide between the types of ablation available?
Do you offer RT both to the prostate and synchronous oligometastases in de novo oligometastatic prostate cancer?
How do you reconcile discordant PSMA and MRI findings in patients undergoing definitive radiotherapy for prostate cancer?
What is the rationale for the recent change in the NCCN criteria for very high risk prostate cancer?
What is your experience with Pylarify vs. Posluma PSMA PET for prostate cancer and is one preferred over the other?
Under what circumstances would you treat prostate cancer without a biopsy?
Given results of the RADICALS trials, is LT-ADT standard of care for salvage prostate RT?
For a patient post-prostatectomy with a high PSA (>1), a negative MRI pelvis, and a negative PSMA PET scan, do you pursue any other imaging?
How would you approach patients with high-risk localized prostate cancer (per STAMPEDE criteria) receiving RT and concurrent ADT but are unable to tolerate abiraterone secondary to toxicities?
